Immunicum appoints Karin Hoogendoorn as head of CMC
Ms. Hoogendoorn is a seasoned expert in the development of biotechnological products and has lead successful CMC and CMC-regulatory efforts for a variety of products within positions at, among others, Novartis AG, Janssen Biologics BV and Crucell Holland BV.
Ms. Hoogendoorn joins Immunicum with 20 years of experience within the biotechnology and pharmaceutical industry.
Most recently, she served as Associate Director Regulatory CMC in the Cell and Gene therapy unit at Novartis AG where she was in charge of Global Regulatory CMC and overall CMC strategy for cell and gene therapies.
Ms. Hoogendoorn also spent seven years at Janssen Biologics BV (previously Centocor BV) as Associate Director Global Regulatory Affairs-CMC where she was responsible for writing and reviewing quality sections of regulatory dossiers for advanced therapy medicinal products (i.e. cell based medicinal products and combination products) and monoclonal antibodies.
In the past, she also held different CMC roles at companies such as Crucell Holland BV and OctoPlus Development BV.
Ms. Hoogendoorn has a PharmD from Utrecht University, the Netherlands, and holds a MSc in Biology & Bio Pharmaceutical Sciences from Leiden University, the Netherlands.
Apart from her role at Immunicum, she also serves as Senior Consultant CMC and CMC-RA at Quality RA BV in Leiden, the Netherlands. ■